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INTRODUCTION
Smooth muscle forms the contractile portion of many organs like blood vessels, uterus,
stomach, intestines, urinary bladder and airways. Consequently, abnormalities of their
contractile function can cause a range of diseases such as high blood pressure, asthma,
coronary and cerebral artery spasms. In spite of their important role in most bodily
functions, the precise mechanism regulating smooth muscle cell contraction is still not
completely known. The understanding of the fundamental mechanism of regulation of
smooth muscle function is essential for the improvement of treatment of diseases due to
abnormalities of smooth muscle contraction.
1.1 Characteristics of the smooth muscle cell
Smooth muscle cells are mononucleate, fusiform and, unlike striated muscle, do not show
evident cross-striations by electron or light microscopy. They contain thick, thin and
intermediate filaments, but these are not highly organized into sarcomeres as in skeletal
and cardiac muscle. The thick and thin filaments, composed mainly of myosin and actin
respectively, form the contractile apparatus, whereas the intermediate filament has a
structural function (Gabella 1984; Gunst 1999).
The thick filaments are nearly aligned with the long axis of the cell, and surrounded by
roughly 15 thin filaments, as observed in vascular muscle. The thin filaments run parallel
with the thick filaments and insert acutely into dense areas of plasma membrane. The
membrane-associated dense plaques are connected to each other in adjacent cells,
constituting the so called attachment plaques, thus conferring mechanical coupling
between the cells (Gabella 1984; Gunst 1999). Similar dense bodies are also observed
scattered in cytosol of smooth muscle cells. The thin filaments can be seen attached to
the opposite ends of these dense bodies, which are believed to be analogous to the Z-line
bands of striated muscle, providing anchorage for the thin filaments (Gabella 1984).
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The cellular content of actin and tropomyosin in smooth muscle is about twice that of
skeletal muscle, but the myosin content in smooth muscle is only one third of that of
skeletal muscle. Despite the lower myosin content, smooth muscle is capable of
generating the same isometric force per cross-sectional area as the skeletal muscle.
Furthermore, smooth muscle contracts slower and maintains tension at a much lower
energy cost than skeletal muscle (Eddinger 1998). 
The structure of the thick filaments in smooth muscle is supposed to be very different to
that in skeletal muscle. Unlike the bipolar arrangement of the thick filaments in skeletal
muscle, the smooth muscle thick filaments form a side-polar structure, with the myosin
heads facing in the same direction on each side of the molecule, without a central bare
zone (Xu 1996).
1.2 Thick filament
1.2.1 Molecular structure of myosin 
The thick filaments of smooth muscle are mainly composed of myosin II, the major
molecular motor protein of muscle and non-muscle cells, responsible for muscle
contraction and cell motility, generated by cyclic interaction with actin. Myosin II is a
hexameric molecule, consisting of two heavy chains (MHC), each with a molecular weight
of approximately 200 kDa, and two pairs of light chains (MLC). Each MHC has an
asymmetric globular amino terminal head domain, linked to a long á-helical tail and a
short non-helical C-terminal tailpiece of approximately 34-44 amino acids (Adelstein and
Sellers 1996; Gunst 1999).
The myosin heads are composed of a globular motor domain and an á-helical neck
region. The motor domain contains the ATP and actin binding domains (Rayment et al.
1996). The function of the neck region of myosin is not completely clear. Besides its
association with the myosin light chains, it may act as a rigid “lever arm” to amplify small,
nucleotide-mediated conformational changes in the head (Whittaker et al. 1995).
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Figure 1. Model of myosin molecule structure, showing the two globular heads,
connected to a long á-helical tail. Each head consists of a motor domain, which contains
the actin and ATP binding domains, and a neck region, that is associated with MLC20 and
MLC17.
Additionally, a correlation between the length of myosin neck and filament sliding velocity
in an in vitro motility assay was suggested (Uyeda et al. 1996).
Each myosin head is associated with one essential and one regulatory light chain. Both
light chains diverge in their molecular weight, structure and function. Phosphorylation of
the 20 kDa MLC (MLC20), also called regulatory or phosphorylatable light chain, triggers
the myosin ATPase activity and initiates smooth muscle contraction (Bárány and Bárány
1996; Kamm and Stull 1985). The function of the 17 kDa MLC (MLC17), named essential
light chain, is still not clear. It was suggested that it participates in the active site of myosin
(Okamoto 1986). In addition, a correlation between the expression of the acidic MLC17
isoform and shortening velocity has been observed (Morano et al. 1993, 1997).
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The myosin tails are responsible for assembly into functional thick filaments (Trybus
1996). The importance of the tail domain for cellular function of myosin has been
investigated with mutant cells that express a truncated form of myosin, similar to the
proteolytic fragment heavy meromyosin (HMM). HMM contains the two globular heads
and approximately 1/3 of the tail domain. These mutant cells were motile, but showed a
great impairment of their general motility and their developmental ability (De Lozanne and
Spudich 1987; Wessels et al. 1988), indicating that the assembly portion of the tail
domain is essential for the accurate function of myosin. The function of the non-helical
tailpiece remains uncertain. It has been suggested that it modulates filament formation in
non-muscle myosin (Hodge et al. 1992). However, recent studies have shown that the
critical region for filament formation of smooth and non-muscle myosin is the C-terminal
end of the coiled-coil tail domain, but not the non-helical tailpiece (Ikebe et al. 2001).
1.2.2 Myosin heavy chain isoforms
Three different genes coding for myosin heavy chain are expressed in smooth muscle
cells, namely one for smooth muscle specific myosin heavy chain (SM-MHC) and two
genes coding for non-muscle myosin heavy chain (NM-MHC), termed NMA with 196 kDa
and NMB with 198/200kDa (Kawamoto and Adelstein 1991; Kelley 1997). 
Four mRNA variants of SM-MHC are generated by alternative splicing at the 5´ and 3´ end
of the primary transcript. Alternative splicing of a 39 nucleotide (nt) exon at the 3´ end
produces two SM-MHC isoenzymes with 204 kDa (SM1) and 200 kDa (SM2)  (Nagai et al.
1989; Babij and Periasamy 1989). This exon contains a stop codon. As a result, its
inclusion causes the short carboxyl terminus of 9 amino acids of SM2, while splicing of
this exon results in the longer carboxyl terminus of 43 amino acids of SM1. Additional
alternative splicing of a 21 nt exon at the 5´ end close to the ATP binding site generates
the inserted seven amino acids (SM1B, SM2B) or non-inserted (SM1A and SM2A)
isoforms (Babij et al. 1991; White et al. 1993). 
The NM-MHC isoforms A and B are encoded by two separate genes, located on
chromosomes 22 and 17 respectively (Saez et al. 1990; Simons et al. 1991). They have
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been named non-muscle myosin, since they are not specific for smooth muscle cells, but
are also expressed in other non-muscular cell types (Kelley 1997). Two additional NMB
isoforms have been reported, generated by alternative splicing in the head region near the
actin-binding site (NB1 with 63 nt insertion) and near the ATP-binding site (NB2 with 30 nt
insertion). However, these spliced variants are expressed only in nervous tissue, and not
in smooth muscle or other non-muscle cells (Takahashi et al. 1992).
Gene sequences of smooth and non-muscle MHC have a high degree of homology.
Indeed, smooth and non-muscle myosin are more closely related to each other than to
striated myosin (Miano et al. 1994). Both smooth and non-muscle myosin are regulated by
phosphorylation and dephosphorylation on conserved sites of the regulatory MLC (mainly
at Ser19) by different protein kinases (myosin light chain kinase, Rho-kinase and p21-
activated kinase), inducing high motor activity and filament assembly (Bresnick 1999;
Sellers et al. 1981; Trybus 1996).
1.2.3 Regulation of myosin isoform expression
The expression of SM-MHC and NM-MHC isoforms varies among smooth muscle tissues,
developmental stages and during patho-physiological conditions, suggesting that these
isoforms might have different functions. SM-MHC isoforms are exclusively expressed in
smooth muscle tissues (Miano et al. 1994), whereas NM-MHC isoforms are variously
expressed in different tissues. The expression of myosin isoforms has been studied in
rabbits, rats, and humans, and the relative amount of the different isoforms in a given
tissue appears to be species-dependent (Aikawa et al. 1993; Frid et al. 1993; Kuro-o et al.
1989 and 1991; Zanellato et al. 1990).
In embryonic and perinatal vascular smooth muscle of rabbit and human, SM1 and NM-
MHC are the predominant isoforms expressed,  whereas SM2 appears only after birth in
rabbit (Kuro-o et al. 1989, 1991), or during late fetal development in humans (Aikawa et
al. 1993; Frid et al. 1993). The expression of NM-MHC decreases during postnatal
vascular development in parallel with the increase of SM2 expression. NM-MHC markedly
increases in proliferating smooth muscle cells of arteriosclerotic plaque (Kuro-o et al.
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1991; Zanellato et al. 1990). Additionally, the expression of NM-MHC has been suggested
to be associated with the restenosis after coronary atherectomy in humans (Simons et al.
1993).
In rabbit urinary bladder, SM1 is the predominant isoform in newborn. With development,
SM1 is down-regulated while SM2 expression increases (Arafat et al. 2001; Chiavegato et
al. 1993). NMA isoform is expressed in both adult and newborn bladders, whereas NMB
expression is verified at low levels only in newborn bladders (Arafat et al. 2001). In
hypertrophied bladder muscle, SM2 is down-regulated in parallel with increase of NMA,
but it returns to normal levels with reversal of the hypertrophy (Chiavegato et al. 1993).
In human myometrium, similar amounts of SM1, SM2 and NMA are expressed in the adult
state. In the hypertrophied human myometrium, however, NMA decrease is linked to an
increase of SM2 (Morano et al. 1997). In rat hypertrophied myometrium, NM-MHC is also
down-regulated, but in favor of SM1 (Morano et al. 1993).
The expression of SMA and SMB is also diversely regulated in a tissue-specific manner.
In adult rat, SMB is predominantly expressed in small arteries, bladder, intestine, and
stomach, whereas SMA is mainly found in aortic and vena cava vascular smooth muscle.
In most rat fetal smooth muscle, both SMA and SMB isoforms are expressed, but the
expression of SMA is significantly smaller than of SMB (Wetzel et al. 1998; White et al.
1993, 1998).
1.2.4 Functional role of different myosin isoforms
Several studies have reported a functional correlation with different expression of these
isoforms in smooth muscle tissues, but a clear relationship remains to be determined.
Because of the proximity of the ATP binding site, the 5' insert is believed to have a
functional significance. In fact, studies using in vitro motility assay revealed that SM-MHC
with the 5´-insert (SMB) has a higher Mg2+-ATPase activity and moves actin filaments
faster than the SM-MHC without 5´-insert (SMA) (Kelley et al. 1993; Rovner et al. 1997).
It has been suggested that the extra insertion adjacent to the nucleotide binding site
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increases both the rate of ATP binding to and ADP release from cross-bridges (Lauzon et
al. 1998), leading to an increase in the shortening velocity. On the contrary, some studies
have not found an association between 5' splicing of MHC and speed of smooth muscle
shortening (Haase and Morano 1996; Morano et al. 1993, 1997).
In regard to C-terminal SM-MHC isoforms, an increased shortening velocity of
myometrium from oestrogen-treated rats has been attributed to an increased amount of
SM1 (Hewett et al. 1993). However, Morano et al. (1993) credited the increased
shortening velocity of pregnant rat uterus to changes in the expression of MLC isoforms
and not to SM1 and SM2 expression. Consistent with this idea, no differences have been
found in moving actin filaments by SM1 and SM2 in the in vitro motility assay (Kelley et al.
1992). Moreover, experiments with single smooth muscle cells have shown that the
different expression of SM1 and SM2 mainly affects the final length to which the cell can
contract and not the shortening velocity (Meer and Eddinger 1997). 
The interpretation of these studies is further complicated by the diverse association of
different head domain isoforms with different tail domain isoforms, as well as with different
light chain isoforms, which have also been reported to contribute to differences in myosin
kinetic (Murphy et al. 1997). An inverse correlation between the expression of basic MLC17
isoform (MLC17b) and shortening velocity has been noted (Malmqvist and Arner 1991;
Matthew et al. 1998). Similarly, an increased relative content of acidic MLC17 isoform
(MLC17a) has been observed in parallel with increased shortening velocity (Morano et al.
1993, 1997) and ATPase activity (Helper et al. 1988). However, this correlation in the in
vitro motility assays is still controversial (Hasegawa and Morita 1992; Kelley et al. 1993;
Rovner et al. 1997). In addition, experiments with unloaded shortening velocity in single
smooth muscle cells showed no correlation between shortening velocity and MLC17a and
MLC17b isoforms expression (Eddinger et al. 2000). 
Non-muscle myosin II is known to be directly involved in cytoskeletal rearrangements of
non-muscle cells such as cell motility, cell division, cell aggregation and cell morphology
(Bresnick 1999; Tan et al. 1992). In smooth muscle cells, however, the functional
significance of non-muscle myosin is still unknown. It has been observed that antisense
oligonucleotides to NM-MHC suppress smooth muscle cell proliferation in vitro (Simons
and Rosenberg 1992), suggesting an involvement of non-muscle myosin in the regulation
 Introduction  .  15
of smooth muscle cell proliferation. Similar to SM-MHC isoforms, NMA and NMB also
differ in their mechanical properties. In the in vitro motility assay, it has been observed
that NMA has greater Mg2+-ATPase activity and moves actin filaments faster than NMB
(Kelley et al. 1996). The true role of non-muscle myosin in smooth muscle cell function,
however, remained unknown.
1.3 Thin filament
Monomeric globular actin (G-actin) aggregates to form the thin filaments (F-actin),
responsible for interaction with myosin to produce force. F-actin consists of a double á-
helical structure of uniformly oriented G-actin. Each G-actin is composed of a single
polypeptide with 375 amino acids and a molecular weight of 42 kDa, associated with one
molecule of noncovalently bound ATP. The smooth muscle tissues express four different
actin isoforms: á and ã smooth muscle actin, and â and ã non-muscle actin. Sequence
analysis shows that actin is highly conserved, with only 5% amino acids differing between
the diverse isoforms (Gunst 1999; Pollard and Cooper 1986). The expression of different
actin isoforms appears to modify during development and patho-physiological conditions
(Cavaillé et al. 1986; Eddinger and Murphy 1991; Malmqvist et al. 1991). However,
whether the different expression of actin isoforms has a physiological significance
concerning the activation of myosin ATPase is still not known.
In addition to actin, the thin filaments contain tropomyosin, caldesmon and calponin, but
unlike skeletal and cardiac muscles, do not have troponin.
Tropomyosin has a dimeric á-helical coil structure, arranged along the actin filaments. It
binds to F-actin at a ratio of 1 molecule of tropomyosin per 7 monomeric units of actin.
The length and the periodicity of tropomyosin in smooth and striated muscle are identical,
but its function in smooth muscle is still unknown (Gunst 1999).
Caldesmon (CaD) is a long flexible protein, consisting of a single polypeptide chain with
a molecular weight of 93 kDa (Graceffa et al. 1988; Stafford et al. 1994). It has a central
rigid domain with an á-helical structure, and a flexible domain at both ends with the actin
 Introduction  .  16
binding sites (Mabuchi et al. 1993; Wang et al. 1991a, 1991b). CaD has been shown to
bind to F-actin, myosin, tropomyosin and calmodulin (Horowitz et al. 1996; Wang et al.
1991a). It has been observed that CaD can inhibit actin-activated ATPase activity of
smooth muscle myosin and actin motility in the in vitro motility assay (Hemric and
Chalovich 1988; Shirinsky et al. 1992). Its inhibitory activity increases in the presence of
tropomyosin and it is also modulated by Ca2+-calmodulin, that greatly reduces the affinity
of CaD for actin (Shirinsky et al. 1992; Smith et al. 1987). Because of these properties,
CaD has been proposed to act as a thin filament regulatory protein, having a similar
function to troponin in skeletal muscle (Smith et al. 1987). Additionally, the observation
that CaD also binds to myosin has led to the suggestion that CaD acts as a cross-linker of
actin and myosin, promoting stabilization of dephosphorylated myosin into thick filaments
and thin-thick filament ?tethering” (Ikebe and Reardon 1988; Katayama et al. 1995).
However, this property has been observed only in vitro, and it has not been supported by
findings of electron microscopy (Moody et al. 1990).
Calponin (CaP) is a flexible and long protein composed of a single polypeptide chain with
a molecular mass of around 30 kDa (Stafford et al. 1995; Takahashi et al. 1986). It binds
to F-actin and myosin (Horowitz et al. 1996; Winder and Walsh 1993). CaP has been
shown to inhibit actomyosin ATPase activity and actin filament motility in vitro, but in
contrast to caldesmon, tropomyosin does not increase the inhibitory activity of CaP
(Shirinsky et al. 1992; Winder and Walsh 1990). It is localized in both cytoskeletal and
contractile domains (North et al. 1994b), but studies with immunoelectron microscopy
have shown a preferential localization of CaP at the periphery of cytoskeletal domain in
association with desmin (Mabuchi et al. 1996).
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Figure 2. Cross-bridge cycle
1.4 Smooth muscle contraction
Smooth muscle contraction is thought to occur primarily according to the cross-bridge
cycling model presented for striated muscle (Huxley 1957): it was suggested that smooth
muscle contracts through sliding of adjacent thick and thin filaments against to each other,
without changes in the length of the filaments themselves, driven by the cyclic interaction
of myosin with actin (Kamm and Stull 1985).
1.4.1 Actin-myosin interaction
The smooth muscle contraction results from cyclic interaction of myosin cross-bridges with
actin, energized by ATP hydrolysis at the globular myosin head (Arner and Pfitzer 1999).
In the absence of ATP, the head portion of the myosin (M) molecules attaches with high
affinity to actin (A) filaments. The binding of ATP to myosin (step 1) reduces its affinity for
actin, that leads to detachment of myosin from actin (step 2). Free myosin hydrolyzes ATP
to ADP and Pi (step 3) and myosin-products complex reattaches to actin in a weak binding
state (step 4). As actin rebinds to myosin, Pi is released (step 5), leading to a
conformational change, which makes the myosin pull against the actin filament, followed
by isomerisation (step 6) and ADP release (step 7). Thus, the transduction of chemical
energy into directed movement occurs during product release and not during the
hydrolysis step (Arner and Pfitzer 1999; Rayment et al. 1996).
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1.4.2 Activation of smooth muscle contraction
A rise in intracellular Ca2+ concentration ([Ca2+]i) is the main mechanism for initiating
contraction in both striated and smooth muscle cells (Filo et al. 1965). However, the
mechanisms whereby Ca2+ activates contraction vary essentially between the different
muscle types. In smooth muscle cells, the increased [Ca2+]i binds to calmodulin (CaM) and
the Ca2+-calmodulin complex activates myosin light chain kinase (MLCK). Activated
myosin light chain kinase phosphorylates the regulatory light chains of myosin (MLC20)
mainly at Ser-19 (Gallagher et al. 1997; Ikebe and Hartshorne 1985). Phosphorylation of
MLC20 leads to myosin-actin interaction, increase in myosin ATPase activity, and smooth
muscle contraction (Kamm and Stull 1985).
The decrease in [Ca2+]i results in dissociation of Ca
2+.CaM.MLCK complex, leading to
inactivation of MLCK, thus permitting dephosphorylation of MLC20 by myosin light chain
phosphatase (MLCP), deactivation of actomyosin ATPase and initiation of smooth muscle
relaxation (Kamm and Stull 1985).
1.4.3 Regulation of intracellular Ca2+ concentration
The increase of [Ca2+]i during contraction results from influx of Ca
2+ through voltage-
dependent channels and from Ca2+-released from intracellular stores (Bolton et al. 1999).
In smooth muscle cells, two types of voltage-dependent Ca2+-channels have been
described, T-type (transient) and L-type (long lasting) channels (Bolton et al. 1999).
Depolarization of cell membrane by action potentials or increase in extracellular K+ is the
main mechanism of L-type Ca2+-channel activation, promoting its change from the closed
to the open state. The smooth muscle cells can also be depolarized by agonists directly
through the opening of nonspecific cation channels and inhibition of K+ channels, or
indirectly through activation of Cl- channels by increased intracellular Ca2+, which results
from agonist-dependent Ca2+ release from intracellular stores (Rembold 1996).
The release of Ca2+ from intracellular stores is mediated by the action of inositol 1,4,5-
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trisphosphate (InsP3) and by Ca
2+-induced Ca2+ release. InsP3 is produced through
activation of phospholipase C (PLC) by the binding of agonists to receptors coupled to G-
proteins. Activated PLC hydrolyzes a membrane lipid, phosphatidylinositol 4,5-
biphosphate (PIP2), to InsP3 and 1,2-diacylglycerol (DAG). InsP3 translocates from the
plasma membrane to a specific receptor on the sarcoplasmic reticulum, thereby triggering
Ca2+ release from the intracellular store (Bolton et al. 1999; Rembold 1996). The
physiological role of InsP3 in Ca
2+ release in smooth muscle cells has been extensively
confirmed through the use of heparin, an inhibitor of InsP3-receptor (Kobayashi et al.
1989); through stimulation of skinned smooth muscle with InsP3, which leads to Ca
2+
release and subsequent contraction (Somlyo et al. 1985); and through kinetic studies
showing InsP3 release followed by increase in Ca
2+ and contraction (Somlyo et al. 1992).
The Ca2+ release induced by InsP3 is also modulated by Ca
2+
i itself, that potentiates the
opening of InsP3-receptor channel if [Ca
2+]i is below 300 nM, but inhibits it above this
concentration (Iino and Tsukioka 1994).
It has been also suggested that Ca2+-induced Ca2+ release through activation of ryanodine
receptors participates in Ca2+-regulation of smooth muscle cells (Herrmann-Krank 1991;
Xu et al. 1994). However, its existence under physiological conditions remains unclear. In
contrast, the influence of [Ca2+]i in InsP3-mediated Ca
2+ release mentioned above might
functionally act as a Ca2+-induced Ca2+ release-like mechanism in a specific range of
[Ca2+]i.
1.4.4 Regulation of smooth muscle contraction
A rise in [Ca2+]i and a subsequent Ca
2+.CaM.MLCK-dependent phosphorylation of MLC20
is the main triggering mechanism for activation of smooth muscle contraction (Somlyo and
Somlyo 1994). However, it has been observed that after the initial increase in [Ca2+]i, the
levels of [Ca2+]i, and MLCK activity decline to near-resting levels, but MLC20
phosphorylation and force are sustained. Furthermore, stimulation of smooth muscle by
several agonists induces MLC20 phosphorylation and contraction without a proportional
increase in [Ca2+]i, the so called Ca
2+-sensitization. Thus, it has been suggested that
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modulation of the sensitivity of MLC20 phosphorylation to Ca
2+ is an additional meaningful
mechanism of regulation of smooth muscle contraction (Somlyo and Somlyo 1994). It is
generally believed that the main mechanism of Ca2+-sensitization is through inhibition of
MLCP, with alteration of the balance MLCK/MLCP in favor of MLCK, which would lead to
increase MLC20 phosphorylation at a given [Ca
2+]i (Kitazawa et al. 1991; Somlyo and
Somlyo 1994).
Smooth muscle MLCP is composed of three subunits: a 110-130 kDa regulatory subunit
(M110-130), a 37-38 kDa catalytic subunit (PP-1C), and a 20 kDa subunit of yet
undetermined function (Hartshorne et al. 1998; Mitsui et al. 1992; Shirazi et al. 1994). The
M110-130 subunit is responsible for selectivity for myosin, binding to both phosphorylated
myosin and PP-1C, and additionally for regulation of activity of PP-1C (Hartshorne et al.
1998; Shirazi et al. 1994). 
The main pathways proposed for MLCP inhibition involve protein kinase C, RhoA/Rho-
kinase and arachidonic acid.
1.4.4.1  Protein kinase C
The involvement of protein kinase C (PKC) in smooth muscle contraction was firstly
suggested by the observation that tumor-promoting phorbol esters, which specifically
activate PKC, induce slow sustained contractions in several types of smooth muscle
(Chatterjee and Tejada 1986; Danthuluri and Deth 1984). Additionally, many agonists
have been shown to induce sustained increases in 1,2-diacylglycerol (DAG), the
physiological activator of PKC (Griendling et al. 1986; Takuwa et al. 1986). Furthermore,
recent studies using specific PKC inhibitors in intact and permeabilized smooth muscle
have confirmed the role of PKC in sustained contraction under physiological conditions
(Lee et al. 1999; Murthy et al. 2000).
DAG is generated through phospholipase C (PLC)-mediated phosphatidylinositol 4,5-
biphosphate (PIP2) hydrolysis and by phospholipase D (PLD)-mediated hydrolysis of
phosphatidylcholine (PC). Unlike PIP2 hydrolysis, hydrolysis of PC does not result in the
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release of inositol 1,4,5- trisphosphate (InsP3) and consequently there is no release of
Ca2+ from intracellular stores (Lee and Severson 1994). Some studies have shown that
PC hydrolysis is the major source for sustained DAG formation in agonist-stimulated
smooth muscle cells (Lee and Severson 1994). During tone maintenance, low [Ca2+]i
levels are observed. Thus, the stimulation of PKC, mediated by PC hydrolysis, is
consistent with the sustained phase of agonist-induced contraction. 
It has been shown that PKC can phosphorylate MLC20 at Ser-1, Ser-2 and Thr-9 in vitro
(Ikebe et al. 1987). However, the PKC-induced phosphorylation of MLC20 is not correlated
with increase of myosin ATPase activity, or with filament movement in the in vitro motility
assay (Ikebe et al. 1987; Umemoto et al. 1989). In addition, stimulation of smooth muscle
with agonists known to activate PKC is not accompanied by phosphorylation of MLC20 at
PKC-specific sites (Singer et al. 1989). In contrast, the mechanism whereby PKC
mediates Ca2+-sensitization may be through inhibition of myosin light chain phosphatase
(Itoh et al. 1993; Masuo et al. 1994). Indeed, recent studies have shown that PKC
phosphorylates CPI-17, an endogenous inhibitor of MLCP. PKC-induced phosphorylation
of CPI-17 has been shown to induce Ca2+-sensitization through inhibition of MLC20
dephosphorylation, supporting CPI-17 as a physiological mediator of PKC-induced Ca2+-
sensitization in smooth muscle (Eto et al. 1995; Kitazawa et al. 2000; Li et al. 1998;
Senba et al. 1999).
Additionally, atypical PKC isoforms activated by arachidonic acid have also been shown
to inhibit MLCP activity (Gailly et al. 1997). Furthermore, PKC is also believed to
participate in thin filament regulatory mechanism of smooth muscle contraction. PKC may
directly or indirectly phosphorylate the thin filament associated proteins caldesmon and
calponin, which would relieve their inhibitory function, allowing actin-myosin interaction
and contraction (Horowitz et al. 1996; Rokolya et al. 1994; Winder and Walsh 1993).
1.4.4.2  RhoA/Rho-kinase pathway
The RhoA/Rho-kinase pathway is also believed to play a significant physiological role in
Ca2+-sensitization. Experiments with permeabilized smooth muscle have shown a Ca2+-
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sensitization effect of GTPãS-bound RhoA, which was blocked by ADP-ribosylation of
RhoA (Hirata et al. 1992). Moreover, the highly specific antagonist of Rho-kinase, Y-
27632, inhibited the tonic phase of agonist-induced contractions in intact and
permeabilized smooth muscle (Fu et al. 1998; Uehata et al. 1997).
RhoA is a member of the Rho family of low molecular weight monomeric G-proteins. It is
active in GTP-bound and inactive in GDP-bound forms (Nobes and Hall 1994). In resting
smooth muscle, most of RhoA is localized in cytosol, associated with RhoGDI (guanine
nucleotide dissociation inhibitor). Following the stimulation of G-protein coupled receptors
by some agonists, RhoA.RhoGDI is activated by Rho-GEFs (guanine nucleotide exchange
factors) that catalyze GTP-GDP exchange on RhoA, succeeded by translocation of
RhoA.GTP to the cell membrane (Gong et al. 1997). In plasma membrane, RhoA.GTP
activates Rho-kinase, which subsequently phosphorylates the regulatory subunit of MLCP,
M110-130, resulting in inhibition of the MLCP activity (Feng et al. 1999b; Kimura et al. 1996;
Nobes and Hall 1994). Furthermore, recent studies have shown that Rho-kinase can also
phosphorylate and activate CPI-17, an endogenous inhibitor of MLCP (Koyama et al.
2000).
1.4.4.3  Arachidonic acid
Arachidonic acid, released by certain agonists, is also considered as a Ca2+-sensitizing
agent. It has been shown to inhibit MLCP directly in vitro through dissociation of the
regulatory from the catalytic subunit of MLCP, leading to increased MLC20 phosphorylation
at constant Ca2+ (Gong et al. 1992). More recent studies have shown that arachidonic acid
can also activate Rho-kinase, independently of RhoA (Araki et al. 2001; Feng et al.
1999a; Fu et al. 1998). Moreover, arachidonic acid has been shown to activate atypical
PKC isozymes, thereby inhibiting MLCP activity (Gailly et al. 1997).
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1.4.4.4  Thin filament regulation 
Thin filament regulation is another mechanism proposed to explain the maintenance of
tone despite low MLC20 phosphorylation levels observed in smooth muscle. It is believed
that the proteins responsible for thin filament regulation are caldesmon and calponin,
since both molecules have been shown to bind actin and inhibit actomyosin ATPase in
vitro (Hemric and Chalovich 1988; Shirinsky et al. 1992; Winder and Walsh 1990).
With the observation that caldesmon (CaD) can inhibit myosin ATPase and cross-link
actin and myosin in vitro, a dual function for CaD has been proposed (Horowitz et al.
1996). According to this model, CaD is attached to actin, leading to a decrease of the
affinity between actin and myosin. Binding of CaD to myosin promotes stabilization of the
dephosphorylated thick filaments. Upon stimulation, CaD then detaches from the MLC20-
phosphorylated thick filaments and switches the thin filament into the “on-state”, thus
permitting muscle contraction. During tone maintenance, CaD reappears to “tether” the
thick and thin filaments together and to stabilize the dephosphorylated myosin filaments.
The inhibitory function of CaD could be relieved by CaD phosphorylation, induced by
PKC, mitogen-activated protein kinase or by binding to Ca2+-calmodulin (Adam and
Hathaway 1993; Smith et al. 1987; Tanaka et al. 1990). Although many in vitro studies
suggest the regulatory role of CaD in smooth muscle contraction, their in vivo function is
still not confirmed (Horowitz et al. 1996).
Calponin has also been observed to bind to actin and to inhibit actin-activated myosin
ATPase and actin filament movement over phosphorylated myosin in the in vitro motility
assay (Shirinsky et al. 1992; Winder and Walsh 1990). It has been proposed that its
inhibitory activity would be relieved by phosphorylation, induced by PKC, Ca2+-calmodulin-
dependent kinase II or other Ca2+-binding proteins (Winder and Walsh 1990, 1993).
However, its physiological role in smooth muscle contraction is still unclear, since most
data has been achieved from in vitro studies. In addition, its predominant distribution in
the cytoskeletal domain rather than in the contractile apparatus suggests that it does not
function as a contractile regulatory protein, but that it possibly promotes the interaction
between actin and cytoskeletal proteins (Mabuchi et al. 1996). Moreover, a recent study
using a calponin knockout mouse model showed no difference in the Ca2+- and agonist-
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induced isometric force in the smooth muscle preparations in the absence of calponin
(Matthew et al. 2000).
1.4.4.5  Latch-bridges hypothesis
The “latch” concept originated from the observation of force maintenance in arterial
smooth muscle, despite low levels of phosphorylation in parallel with decreased
shortening velocity (Dillon et al. 1981). According to this hypothesis, dephosphorylation of
already attached cross-bridges would decrease the detachment rate, forming a “latch
bridge”. Thus, latch-bridges are attached, dephosphorylated, slowly cycling cross-bridges,
that sustain force but inhibit shortening (Dillon et al. 1981). Besides dephosphorylation of
previously attached cross-bridges, a “cooperative attachment” of dephosphorylated cross-
bridges may also contribute to the latch phenomenon. Thus, the attachment of cross-
bridges would increase affinity and attachment of the neighboring cross-bridges to actin
(Somlyo et al. 1988).
This concept is consistent with observations that phosphorylation of MLC20 increases the
release of Pi from actin-myosin-ADP-Pi forming the strongly attached actin-myosin-ADP
state (Greene and Sellers 1987), and that tonic smooth muscle myosin has a high affinity
for ADP (Fuglsang et al. 1993). However, the latch bridge could not been isolated
biochemically until now, and the possibility of a positive-feedback situation would lead to
an ascending contraction, which argues against the existence of this model (Murphy
1994).
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Figure 3. Proposed models for the regulation of smooth muscle contraction. The
increased  intracellular Ca2+ concentration binds to calmodulin (CaM) and the calcium-
calmodulin complex activates myosin light-chain kinase (MLCK) to phosphorylate the
regulatory light chains of myosin, leading to myosin-actin interaction and contraction.
Phospholipase C- (PLC) and D- (PLD) mediated membrane phospholipids hydrolysis
leads to activation of protein kinase C (PKC), resulting in phosphorylation of CPI-17 and
myosin light phosphatase (MLCP) inhibition. Activation of G–protein coupled receptors
also activates Rho-kinase, which can directly or indirectly inhibit MLCP activity.
Arachidonic acid (AA) can also activate Rho-kinase and PKC and also appears to directly
inhibit MLCP. Abbreviations: CaD, caldesmon; CaP, calponin; DAG, diacylglycerol; InsP3,
inositol1,4,5-trisphosphate; SR, sarcoplasmic reticulum; PIP2, phosphatidylinositol 4,5-
biphosphate; PC, phosphatidylcholine.
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1.5 Aim of the study
Despite the knowledge of many smooth and non-muscle myosin isoforms present in
smooth muscle tissues, it is not clear to what extent the different myosin heavy chain
isoforms contribute to their contractile features. Especially, there is no evidence of the
participation of non-muscle myosin in smooth muscle contraction until now. In order to
determine the physiological significance of smooth muscle specific and non-muscle
myosin heavy chain in smooth muscle contraction, smooth muscle preparations from a
mouse model with a disrupted smooth muscle myosin heavy chain gene were used.
The expression of smooth muscle and non-muscle myosin heavy chain was evaluated by
Western blot analysis using specific anti-smooth muscle and anti-non-muscle myosin
antibodies. Furthermore, the presence of intracellular filamentous structures was
investigated in cultured smooth muscle cells by immunofluorescence using a double
labeling method with specific antibody against smooth muscle and non-muscle myosin
heavy chain and an antibody against smooth muscle á-actin. Finally, the mechanical
analysis was performed by using intact muscle preparations, which provides a good
model for functional studies under physiological conditions.
Thus, it was possible - for the first time - to verify the importance of the non-muscle
myosin heavy chain isoforms for smooth muscle contraction in vivo.
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MATERIALS
2.1 Equipment
Amersham Pharmacia Biotech, Amersham Place, England
Nitrocellulose membrane, Hybond ECL
YT Recorder REC 111
Bio-Rad, Munich
Mini-PROTEAN II Slab Cell
Power supply model 1000/500
HAMEG, Frankfurt am Main
Oscilloscope HM 408






Cold-light sources KL 750











2.2 Chemicals and drugs
Amersham Pharmacia Biotech, Amersham Place, England
Western blotting detection reagents, ECL
Biochrom, Berlin
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Bio-Rad, Munich
Bovine gamma globulin standard
Prestained SDS-PAGE Standards, high range










Gibco BRL, Paisley, Scotland
DMEM
Merck, Darmstadt
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Serva, Heildelberg
Acrylamide 2x































Sodium lauryl sulfate (SDS)
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METHODS
3.1 Animal model
As experimental model, urinary bladder preparations from neonatal wild-type C57BL6
mice as well as from neonatal smooth muscle myosin heavy chain (SM-MHC) deficient
mice of both sexes were employed. The SM-MHC deficient mice were created through
gene-targeting technology, leading to total depletion of SM-MHC isoforms (Morano et al.
2000).
The SM-MHC deficient mice were delivered at the expected Mendelian ratio and had a
normal body weight, suggesting normal fetal development. Most of the SM-MHC deficient
mice died within 12 and 24 hours of life. For this reason, all experiments were performed
with neonatal mice in the first days after birth. 
3.2 Biochemical methods
The expression of SM-MHC and non-muscle myosin heavy chain (NM-MHC) isoforms at
the protein level in bladders of wild-type and SM-MHC deficient mice was evaluated by
Western blot analysis with specific anti-SM-MHC and anti-NM-MHC antibodies.
Urinary bladder was homogenized in lysis buffer, centrifuged at 12000 rpm for 5 min at
4°C. The supernatant was frozen in liquid nitrogen and stored at -80°C until use. A small
aliquot was kept for protein determination.
Lysis buffer consists of SDS 5%; Tris-HCl 50 mM, pH 7,5; saccharose 0.25 M; urea 75
mM; 2-ßmercaptoethanol 60 mM.
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3.2.1 Protein determination
The protein content was determined using the Bradford assay. A standard curve was
constructed using ã-IgG (Bio-Rad). The unknown sample (5 to 40 µl) was mixed with 200
µl of protein reagent (Bio-Rad) and 800 µl distilled water and allowed to stand for 10 min.
The sample was subsequently read in a photometer at 595 nm. Protein concentration of
the unknown sample was determined from the standard curve.
3.2.2 Electrophoretic separation of myosin heavy chain isoforms 
Sample buffer contains 0.5 M Tris-HCl, pH 6.8 12,5% (v/v); glycerol 10% (v/v); SDS 2%
(w/v); 2-ßmercaptoethanol 5% (v/v); bromophenol blue 0,001% (w/v).
SDS electrophoresis buffer contains Tris base 0.025 M; glycine 0.192 M; and SDS 0.1%
(w/v).
All solutions were prepared with bi-distilled water.
The myosin heavy chain isoforms were separated by SDS-polyacrylamide gel
electrophoresis (SDS-PAGE), according to a modified Laemmli gel method (Laemmli
1970). The Mini-Protean II dual slab cell (Biorad) was used, which provides a gel with the
following dimensions: 80 mm wide, 70 mm long and 1.5 mm thick. A 5% separating gel
(see table 1) was prepared and applied between the glass plates. The solution was
covered with distilled water to provide a flat gel surface. After polymerization, a 4%
stacking gel (see table 1) was prepared and applied above the separating gel, after the
water was poured off. A comb was placed into the stacking gel solution, and it was
allowed to polymerize. After polymerization, the comb was removed and each well was
loaded with 25 µg protein. The control wells were loaded with the high-molecular weight
standard kit of Bio-Rad. The protein samples were diluted 1:4 (v/v) with sample buffer and
heated 5 min at 95°C. 
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Separating gel Stacking gel
Distilled water 5.675 ml 3.05 ml
1.5 M Tris-HCl, pH 8.8 2.5 ml —
0.5 M Tris-HCl, pH 6.8 — 1.25 ml
30% Acrylamide/ 0.8% bis 1.67 ml 0.65 ml
SDS 10% 100 µl 50 µl
APS 10% 50 µl 25 µl
Temed 5 µl 5 µl
Table 1. Recipes for separating and stacking polyacrylamide gels, based on the buffer
system of Laemmli.
Electrophoresis was carried out at 220 V. The temperature was kept at 15°C. The gels
were processed for Western blot analysis.
3.2.3 Western blot analysis
Transfer buffer consists of 25 mM Tris base; 192 mM glycine and methanol 20% (v/v).
Blocking buffer contains 15% ovalbumin; 0.1% Tween; 20 mM Tris base and 137 mM
NaCl.
TBS includes 20 mM Tris base, 137 mM NaCl. The pH was adjusted to 7.6 with HCl.
TBST consists of TBS added with Tween 0.1%.
All solutions were prepared with bi-distilled water.
Following SDS-PAGE, the gel was equilibrated for 10 minutes at room temperature in
transfer buffer. The proteins were electrophoretically transferred from gel to nitrocellulose
membrane (Hybond-C, Amersham), for 2 hr at 250 mA.  Following transfer, the
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membrane was incubated with Ponceau staining solution for 10 minutes at room
temperature. The nitrocellulose membrane was blocked with 15% ovalbumin and
incubated with a polyclonal antibody raised against chicken-gizzard SM-MHC (1:100,000)
or with a polyclonal antibody raised against the rod-portion of NM-MHC (1:1250; both
antibodies gift from Prof. Gröschel-Steward, Darmstadt, Germany) overnight at 4°C.
Subsequently, the membranes were incubated with the secondary peroxidase-conjugated
antibody (1:6000 and 1:6500, respectively) for 1 h at room temperature. Between each
step, the membranes were washed by agitating with TBS and TBST solutions. Signals
were then visualized by the enhanced chemiluminescence reaction kit (ECL; Amersham)
using X-ray film (X-Omat; Kodak).
3.3 Immunofluorescence staining of cultured smooth muscle cells
3.3.1 Cell culture
Hepes buffer used for cell culture included 55 mM NaCl, 5.6 mM KCl, 80 mM Na-
glutamat, 2 mM MgCl2, 10 mM glucose and 10 mM Hepes. NaOH was used to adjust pH
to 7.4. Bovine serum albumin (BSA, 1mg/ml), penicillin (0.3 mg/ml) and streptomycin (0.5
mg/ml) were further added in the Hepes buffer.
Papain 0.5 mg and DTT 1 mg were dissolved in 1 ml of Hepes buffer.  Collagenase F and
H were dissolved in Hepes buffer with the ratio F/H of 70%/30%, to give a final
concentration of 1 mg/ml, and 0.01mM CaCl2 was added.
All solutions and materials used directly in contact with the cells were sterile.
Primary cell culture of urinary bladder was performed by a modification of the procedures
described by Gollasch et al. (Gollasch et al. 1992). Neonatal mice were killed by
decapitation and the bladders were excised and placed in Hepes buffer, added with BSA,
penicillin and streptomycin. Adhering fat and connective tissue were removed by
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dissection under microscope and the bladders were minced into small pieces. The
resulting bladder pieces were placed in papain/DTT solution and incubated for 25 min at
36°C. The cell-tissue suspension was centrifuged (900 rpm, 4 min) and the following cell
pellet incubated with collagenase F and H for 15 min at 36°C. After centrifugation (900
rpm, 4 min), the cell pellet was resuspended in DMEM medium containing 20% of fetal
calf serum (FCS) and gentamicin (0.02 mg/ml). Cells were then seeded in plastic culture
dishes and cultivated for 24 hours at 37°C in a humidified atmosphere of 5% CO2/95% air.
3.3.2 Immunofluorescence labeling
Cells were fixed with methanol/acetone (50% v/v) for 10 minutes at -20°C. Double
immunolabeling was carried out with an antibody against smooth muscle á-actin (aS-actin;
clone asm-1, Boehringer) and a polyclonal antibody raised against the rod-portion of NM-
MHC (aNM-MHC). In another set of experiments, double labeling was performed with a
polyclonal antibody raised against chicken-gizzard MHC (aSM-MHC) and with aS-actin
(see above). Secondary antibodies were conjugated with DTAF (anti-rabbit) or Cy3 (anti-
mouse). Nuclei were simultaneously stained by DAPI.
Before each incubation with the antibodies, the cells were pre-incubated with a solution
containing 20 mM Tris-HCl, pH 8.4, 630 mM NaCl, 0.05% Tween 20%, 0.02% NaN3, and
1% BSA-Tris for 30 minutes at room temperature to suppress nonspecific labeling. The
same solution was used to dilute both primary and secondary antibodies. Incubation with
the primary antibodies was executed for 1 hour at 37°C, and with the secondary
antibodies for 30 minutes at 37°C. Control staining was performed with the secondary
antibody alone and minimal background has been observed.
Fluorescence was detected using an Axioplan fluorescence microscope with appropriate
filter systems. Micrographs were followed with an MC100 automatic camera with Kodak
Tmax 400 film. 
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3.4 Mechanical analysis of smooth muscle preparations
3.4.1 Solutions
Krebs-Henseleit solution used for intact muscle preparation contained 119 mM NaCl, 12.2
mM glucose, 4.6 mM KCl, 25 mM NaHCO3, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2.0 mM
CaCl2, 2.0 mM Na-pyruvate, pH 7.4. The solution was gassed with a mixture of 96% O2
and 4% CO2 throughout the experiments.
The strips of smooth muscle were prepared in Krebs-Henseleit solution added with 5 mM
2,3-butanedione monoxime (BDM).
The muscle preparations were activated in KCl depolarization solution or with addition of
phorbol diester in Krebs-Henseleit solution. The KCl depolarization solution was made
with equimolar replacement of NaCl by 50 mM KCl in Krebs-Henseleit solution.
The phorbol diester chosen was phorbol 12, 13-Dibutyrate (PDBu), since this drug has
been reported to be effective in intact muscle preparations (Yoshida et al. 1992). PDBu
was dissolved in dimethylsulfoxide (DMSO), and then diluted to the required
concentrations with distilled water. Final concentrations of DMSO were not greater than
0.1% and did not have significant effects on the contractile response to PDBu.
In some experiments, the muscle preparations were incubated with a specific, cell-
permeable protein kinase C inhibitor (Ro-31-7549), before stimulation with PDBu.
3.4.2 Smooth muscle preparations
Intact urinary bladder strips were prepared from neonatal wild-type as well as from
neonatal SM-MHC deficient mice. The animals were killed by decapitation and the
bladders were quickly taken out and placed in Krebs-Henseleit solution added with BDM.
The bladders were excised and longitudinal strips of the posterior wall of the bladder were
prepared by using micro scissors under a dissecting microscope. The strips were
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approximately 1 mm long and 0.4-0.5 mm wide. During all the procedure the solution was
continuously oxygenated.
3.4.3 Isometric force registration
3.4.3.1  Description of mechanical and electronic equipment
The MLK1 system from Scientific Instruments was used for isometric force measurements
in intact muscle preparations. In this system, the muscle preparations are mounted
horizontally using micro-clamps between a force transducer at one end and a micrometer
at the other end in a tissue bath. The tissue bath chamber is connected to another
chamber, where the incubation solution is oxygenated. This two-chamber system provides
an oxygenation process with minimal interference in the force measurement, since the
gas bubbles do not have direct contact with the incubation solution. The incubation
solution temperature is controlled by a thermostat coupled to the block containing the
solution chambers and is constantly checked with a thermometer. Temperature was 37°C.
After the muscle preparations are mounted, the fibre length can be precisely adjusted
using a micrometer screw, in order to reach the desired resting tension.
This system is connected to a force transducer and a YT recorder. To calibrate the force
transducer, a piece of wire weighting 509.7 mg was hung over the tip of the transducer.
3.4.3.2  Experimental design
The urinary bladder preparations were mounted isometrically in the tissue bath containing
5 ml of Krebs-Henseleit solution and equilibrated for 60 min before the beginning of the
experiments. The tissue bath was continuously gassed with 96% O2 and 4% CO2 and the
temperature was kept at 37°C. Resting tension was adjusted to 0.3 mN.
For isometric force development, bladder preparations were activated in KCl
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depolarization solution or stimulated with PDBu, and force was registered using the YT-
recorder. The isometric force was obtained as total minus passive force (mN).
For the experiments with the protein kinase C inhibitor, the muscle preparations were first
equilibrated in Krebs-Henseleit solution, then incubated with the inhibitor for 20 minutes,
before being stimulated with PDBu. 
3.4.4 Isotonic contraction 
3.4.4.1  Description of mechanical and electronic equipment
For force-velocity determinations, isotonic quick releases under constant load were
applied to the preparations during steady state isometric contraction using the system
MLK1M from Scientific Instruments. In this system, the muscle preparation is mounted
isometrically between a force transducer and a linear motor using micro-clamps,
immersed in oxygenated solution in a two chamber system, connected to a thermostat.
Temperature was 37°C. The muscle strips were stimulated with 50 mM KCl to generate
isometric force.
The constant load unit allows the adjustment of load steps between 3% and 100% of the
isometric force. Load clamping for isotonic shortening is achieved by changing the mode
of operation of the motor from fibre-length control to force control by a trigger signal.
The length signal was additionally amplified 10 times using an external amplifier, in order
to increase the confidence of the length-change measurement.
The system is connected to a PC and the signals were stored and evaluated with MUSKI
software (Scientific Instruments) that controls the selected variables.
The system is also connected to a YT recorder, where isometric force and releases were
continuously recorded.
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3.4.4.2  Experimental design
The muscle preparations were mounted isometrically in 5 ml of Krebs-Henseleit solution
and equilibrated for 60 min before the beginning of the experiments. Throughout the
experiment, the temperature was kept constant at 37°C and the tissue bath was
continuously gassed with 96% O2 and 4% CO2. The length was adjusted so that resting
tension was around 0.3 mN.
The muscle preparations were stimulated in KCl depolarization solution or with PDBu and
isotonic quick releases under constant load were applied during isometric steady-state.
The load steps were adjusted to 3%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%
and 50% of maximal isometric force. The predetermined force was held constant by the
controlled motion of the length step generator which followed the contracting bladder with
the appropriate velocity for 150 ms. The next release started only after the force had
reached the maximal isometric force.
Force was continuously recorded, while force and length at the time of a release were
stored on a computer for later analysis. In the length response three phases are
observed: an initial elastic recoil, followed by a rapid shortening (lasting about 25-75 ms),
and a subsequent phase (around 100 ms) of more steady shortening velocity. Thus, the
steady shortening 100 ms after the release was used for analysis, by fitting a tangent to
the length record (automatically calculated by software MUSKI).
The relation between shortening velocity and force during isotonic contraction was
analyzed using a linearized form of the Hill (Hill 1938) equation:
(P + a) (v + b) = (P0 + a) b
where v is the shortening velocity, P is the force during isotonic contraction, P0 is the
maximal isometric steady-state force and a and b are constants. Through mathematical
calculation it results in:
(P/P0)/b + a/b = (1-P/P0)/v
With this formula, the data can be plotted on a diagram and further interpreted by linear
regression, where X-axis is P/P0, Y-axis is (1-P/P0)/v, slope is 1/b and y-intercept is a/b.
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The maximal shortening velocity (Vmax) was calculated as (1-P/P0)/v when P/P0 = 0. The
shortening velocity was given as muscle length per second (ML/s).
3.5 Statistics
Values are expressed as means ± S.E.M (n = number of experiments). Differences
between means were evaluated using Student´s t-test.
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Figure 4. Western blot analysis of SM-MHC expression in bladder from wild-type (WT)
and homozygous SM-MHC knockout (KO) mice with a polyclonal antibody raised against
chicken-gizzard SM-MHC (1:100000, 20 µg of protein loaded on each lane), showing the
absence of any SM-MHC signal in knockout mice.
RESULTS
4.1 Expression of SM-MHC and NM-MHC isoforms
The presence of smooth muscle myosin heavy chain (SM-MHC) and non-muscle myosin
heavy chain (NM-MHC) isoforms in urinary bladders from wild-type (WT) and homozygous
SM-MHC knockout (KO) animals was evaluated by Western blot analysis. Western blot
analysis using a polyclonal antibody raised against chicken-gizzard SM-MHC showed no
SM-MHC signal in KO bladders (Fig. 4). The expression of NM-MHC was further
evaluated by Western blot analysis using a specific antibody raised against the rod-
portion of NM-MHC, which detected both NMA and NMB isoforms. The NM-MHC signal
was verified in bladders from both wild-type and SM-MHC deficient mice (Fig. 5).
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Figure 5. Western blot analysis of NM-MHC expression of wild-type (WT) and
homozygous SM-MHC knockout (KO) bladders, using an antibody raised against the rod
portion of NM-MHC (1:1250, 20 µg of protein loaded on each lane), revealing similar
expression in both WT and KO bladders.
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4.2 Analysis of myosin filamentous structures in smooth muscle
cells
Since the formation of filamentous structures of myosin is considered to be a prerequisite
for muscle contraction, NM-MHC structures were investigated in primary cultures of
bladder cells by immunofluorescence microscopy. A double labeling method was used
with a specific antibody raised against the rod-portion of NM-MHC (aNM-MHC) and an
antibody against smooth muscle á-actin (aS-actin), as a smooth muscle cell marker. The
primary antibodies were visualized with an anti-rabbit and an anti-mouse secondary
antibodies, labelled with DTAF (green) and Cy3 (red) respectively. As seen in figure 6,
smooth muscle cells prepared from the bladders of both wild-type (WT) and homozygous
SM-MHC knockout (KO) mice showed longitudinally arranged intracellular NM-MHC
filamentous structures.
In another set of experiments, immunolabeling of smooth muscle cells from the bladders
of both wild-type and knockout mice was performed using an antibody raised against
chicken gizzard SM-MHC (aSM-MHC) and the aS-actin antibody. The primary antibodies
were visualized with an anti-rabbit and an anti-mouse secondary antibodies as described
above. As can be seen in figure 7, longitudinally arranged intracellular filamentous
structures of SM-MHC were observed in smooth muscle cells prepared from wild-type
mice, but not in smooth muscle cells from knockout mice. The smooth muscle cells were
identified by reaction with the aS-actin antibody.
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Figure 6. Immunofluorescence micrographs of cultivated smooth muscle cells obtained
from the bladders of wild-type (WT; left panels) and homozygous SM-MHC deficient (KO;
right panels) mice. Immunoreactions were carried out using an anti-non-muscle myosin
heavy chain (aNM-MHC; upper panels, green) and an anti-smooth muscle á-actin (aS-
actin; lower panels, red) antibodies. Longitudinally arranged intracellular filamentous
structures of NM-MHC were observed in smooth muscle cells from both wild-type and
SM-MHC deficient mice. Scale bars represent 5 µm.
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Figure 7. Immunofluorescence micrographs of cultivated smooth muscle cells obtained
from the bladders of wild-type (WT; left panels) and homozygous SM-MHC deficient
(KO; right panels) mice. Immunolabeling was carried out using an antibody raised
against chicken gizzard smooth muscle myosin heavy chain (aSM-MHC; upper panels,
green) and an anti-smooth muscle á-actin antibody (aS-actin; lower panels, red).
Smooth muscle cells from wild-type mice showed longitudinally arranged intracellular
filamentous SM-MHC structures. In smooth muscle cells from knockout mice, however,
no SM-MHC signal could be observed. Scale bars represent 5 µm.
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4.3 Mechanical analysis of smooth muscle preparations
Urinary bladder intact strips prepared from neonatal wild-type and SM-MHC deficient mice
were used for the mechanical analysis of smooth muscle. The bladder preparations were
equilibrated in Krebs-Henseleit solution and then stimulated using prolonged KCl
depolarization (50mM KCl substituted for Na+ in Krebs-Henseleit solution) or with phorbol
12, 13-Dibutyrate (PDBu). 
4.3.1 KCl-induced contraction
4.3.1.1  Isometric contraction of wild-type bladder preparations
Using KCl depolarization of intact bladder preparation from neonatal wild-type mice, an
initial transient state (phase 1) and a subsequent sustained state (phase 2) of isometric
force generation could be distinguished (Fig. 8). Force at the peak of the initial transient
phase was 2.93 ± 0.37 mN i.e. significantly higher than the subsequent sustained force
(0.79 ± 0.19 mN) (p < 0.001, n = 8 animals) (Fig. 10). 
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Figure 8. Original recording of isometric force in bladder preparation of wild-type (+/+)
mouse. KH, Krebs-Henseleit solution (relaxation solution); KCl, depolarization solution
(contraction solution).
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Figure 9. Original recording of isometric force in bladder preparation of homozygous
SM-MHC deficient (-/-) mouse. KH, Krebs-Henseleit solution (relaxation solution); KCl,
depolarization solution (contraction solution).
4.3.1.2  Isometric contraction of knockout bladder preparations
KCl depolarization of intact bladder preparations from SM-MHC deficient mice induced
only a sustained phase (phase 2) i.e. without the initial transient high-force state (Fig. 9).
Sustained contraction of bladder preparations from SM-MHC deficient mice was 0.59 ±
0.07 mN (n = 8 animals) i.e. not significantly different compared with the sustained force
of wild-type preparations, but significantly lower than the initial transient force of wild-type
preparations (p < 0.001) (Fig. 10).
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Figure 10. Statistical comparison of isometric force generated in phase 1 (around 1 min
after onset of KCl stimulation) and phase 2 (around 15 min after KCl stimulation) of
smooth muscle preparations of wild-type (+/+) and phase 2 of homozygous SM-MHC
deficient (-/-) mice. *** denotes p < 0.001; ns, no significance; values are mean ± S.E.M.
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4.3.1.3  Isotonic contraction of wild-type bladder preparations
Bladder preparations from wild-type (WT) mice revealed a maximal shortening velocity
(Vmax) at the peak of phase 1 (initial high force generation) of 0.41 ± 0.03 muscle
length/second (ML/s). Vmax decreased significantly (p < 0.001) 15 min after the onset of
KCl stimulation (phase 2) to 0.15 ± 0.01 ML/s (n = 9 animals) (Fig. 12).
4.3.1.4  Isotonic contraction of knockout bladder preparations
In similar preparations from homozygous SM-MHC knockout mice (KO), Vmax measured
15 min after onset of KCl stimulation (phase 2) was 0.16 ± 0.02 ML/s, i.e. similar to the
corresponding phase of contraction in wild-type mice, but significantly lower (p < 0.001)
than the Vmax of the initial phase of contraction from wild-type preparations. The Vmax of
knockout bladder preparations determined 1 min after onset of KCl stimulation (i.e. prior
reaching steady-state force) was 0.16 ± 0.02 ML/s i.e. not different from the values
obtained 15 min after KCl stimulation (n = 7 animals) (Fig. 12).
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Figure 11. Force-velocity relationship of intact KCl-stimulated bladder preparations
obtained during the peak of the initial transient high-force phase (phase 1; cf. 8) and 15
min after onset of KCl depolarization during the subsequent sustained phase (phase 2;
cf. 8) of wild-type (WT) mice, as well as 1 min (KO 1) and 15 min (KO 2; phase 2, cf. 9)
after KCl depolarization of preparations from knockout (KO) mice. ML/s, muscle length
per second. %F0, force during the quick release expressed in % of maximal isometric
force.
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Figure 12. Statistical comparison of maximal shortening velocity of phase 1 and phase
2 of wild-type (WT) and phase 2 (KO 1, after 1 min; KO 2, after 15 min stimulation) of
SM-MHC knockout preparations. ML/s, muscle length per second. *** denotes p <
0.001; ns, no significance; values are mean ± S.E.M.
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Figure 13. Original recordings of isotonic quick release measurements in intact smooth
muscle preparations. Upper traces, force (µN). Lower traces, the corresponding length
(µm). X axis, time (ms). Shortening velocity is the slope of the curves.
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Figure 14. Concentration-response curve for PDBu in urinary bladder smooth muscle
from neonatal wild-type mice. Each data point represents the mean ± S.E.M. of 5
experiments. Force is expressed as a percentage of the maximal response.
4.3.2 PDBu-induced contraction
4.3.2.1  Isometric contraction of wild-type bladder preparations
Concentration-response curves for PDBu were made using intact bladder preparations
from neonatal wild-type mice, in order to determine the adequate concentration for use.
The concentration-response curves were performed accumulatively, after the response to
the previous concentration had reached a plateau. PDBu (10-8 -10-5 M) was shown to
induce concentration-dependent increased isometric contractions in intact bladder
preparations from neonatal wild-type mice, with half-maximal concentration of 0.56 µM,
and maximal concentration of 10 µM. The contractile response to PDBu (10-5 M) was 0.26
± 0.03 mN in wild-type smooth muscle preparations (n = 8 animals).
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Figure 15. Original recording of isometric force induced by PDBu in intact bladder
preparation of wild-type (+/+) mouse. The arrow indicates the addition of PDBu (10-5 M)
in the tissue bath. KH, Krebs-Henseleit solution (relaxation solution).
4.3.2.2  Isometric contraction of knockout bladder preparations
Bladder preparations from SM-MHC deficient mice (-/-) showed a sustained contraction
after PDBu (10-5 M) stimulation, similar to those of wild-type mice (Fig. 16). The contractile
response to PDBu was 0.39 ± 0.07 mN (n = 8 animals). This value was not significantly
different from PDBu-induced contraction of wild-type preparations (Fig. 17).
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Figure 17. Statistical comparison of isometric force generated upon PDBu stimulation of
bladder preparations of wild-type (+/+) and SM-MHC knockout (-/-) mice. Means are not
significantly different, values are mean ± S.E.M. (n = 8 animals per group).
Figure 16. Original recording of isometric force induced by PDBu in intact bladder
preparation of SM-MHC deficient (-/-) mice. The arrow indicates the addition of PDBu  
(10-5 M) in the tissue bath. KH, Krebs-Henseleit solution (relaxation solution).
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Figure 18. Original recordings of isometric force induced by PDBu in presence of the cell
permeable PKC inhibitor (Ro-31-7549, 5 µM). PDBu (4 µM) was applied into the tissue
bath containing Krebs-Henseleit solution. a, smooth muscle preparation of wild-type (+/+)
mouse. b, smooth muscle preparation of homozygous SM-MHC deficient (-/-) mouse.
KH, Krebs-Henseleit solution (relaxation solution). 
Incubation with the PKC inhibitor, Ro-31-7549, completely abolished the force generated
upon PDBu stimulation in both smooth muscle preparations from wild-type (+/+) and SM-
MHC deficient mice (-/-) (Fig. 18).
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Figure 19. Original recording of isometric force induced by KCl depolarization after pre-
incubation with PDBu in intact smooth muscle preparation of wild-type mouse. KH,
Krebs-Henseleit solution (relaxation solution); KCl, depolarization solution (contraction
solution).
4.3.2.3  Effect of PDBu on KCl-induced contraction
The effect of PDBu on both phases of KCl-induced contraction was examined in intact
bladder preparations from neonatal wild-type mice. Pre-incubation with PDBu significantly
potentiated the sustained phase of KCl-induced contraction, but had nearly no effect on
the initial phase of contraction (Fig. 19). The effect was expressed as percentage of
isometric force elicited by KCl before incubation with PDBu (force after PDBu/force before
PDBu . 100). Sustained force (phase 2) was 190 ± 24.5% of isometric force before PDBu,
whereas the transient phase (phase 1) of KCl-induced contraction increased only to 110.2
± 2.5% (p < 0.01, n = 6 animals per group) upon treatment with PDBu (Fig. 20). 
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Figure 20. Statistical comparison of the effect of pre-treatment with PDBu on initial
(phase 1) and sustained (phase 2) phases of KCl-induced contraction, expressed as
percentage of isometric force elicited before PDBu. ** denotes p < 0.01; values are mean
± S.E.M.  (n = 6 animals per group).
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DISCUSSION
The main finding of the present study is that non-muscle myosin heavy chains are
recruited for smooth muscle contraction. This was verified by the observation that smooth
muscle preparations without smooth muscle myosin heavy chain (SM-MHC) expression,
but with normal non-muscle myosin heavy chain (NM-MHC) expression, produced
sustained force of contraction. This force generation is elicited by myosin II, as
demonstrated by cross-bridge cycling (active shortening) of all smooth muscle
preparations in the constant load experiment.
In gene targeted mice, a total depletion of SM-MHC was observed, as demonstrated by
Western blot analysis using an antibody against chicken-gizzard SM-MHC. Additionally,
the absence of SM-MHC was recently confirmed by both Northern blot and Western blot
analysis using antibodies against the isoforms SM1, SM2 and the seven-amino-acid insert
of SM-MHC (Morano et al. 2000). Ablation of the SM-MHC gene, however, did not affect
the expression of non-muscle myosin heavy chain. This was demonstrated by Western
blot analysis with a specific antibody against the rod-portion of NM-MHC, showing that
NM-MHC was normally expressed in SM-MHC deficient mice.
The involvement of NM-MHC in smooth muscle contraction was supported by the
existence of longitudinally arranged NM-MHC filaments in smooth muscle cells from both
wild-type and knockout mice, using immunofluorescence microscopy. The myosin
filaments serve as the basic functional units necessary for contraction. As expected,
smooth muscle cells from knockout mice showed no SM-MHC filaments. Additionally, the
presence of longitudinally arranged filamentous structures of SM-MHC in wild-type
smooth muscle cells confirmed that the cultivation conditions (24h) used in the primary
culture of smooth muscle cells conserved the contractile phenotype.
The mechanical analysis showed that smooth muscle preparations from SM-MHC
deficient mice produced force and active shortening. The force development in the muscle
is correlated with the number of activated cross-bridges, whereas shortening manifests
the cross-bridge turnover rate. Both mechanical and kinetic properties from the muscle
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reflect the actin-myosin interaction. Thus, the force generated by knockout preparations
could only be produced by recruitment of myosin II rather than by changes in the
compliance of elastic elements. The mechanical experiments were realized with intact
muscle preparations, because using this method physiological conditions are preserved.
Therefore, it was possible to verify the physiological significance of non-muscle myosin in
vivo.
Non-muscle myosin II is a ubiquitous cytoskeletal protein, with high homology to smooth
muscle myosin II. In non-muscle cells, it has an important role in various motile events,
like cell division (De Lozanne and Spudich 1987; Fukui et al. 1990), cell motility (Warrick
and Spudich 1987) and cell morphology (Pasternak et al. 1989). NM-MHC is also
expressed in smooth muscle cells under normal physiological conditions and during
pathological processes (Kelley 1997). Moreover, the concentration of NM-MHC in smooth
muscle cells is 2- to 3-fold greater than that of platelets and adrenal medulla (Gaylinn et
al. 1989). Because of this large quantity of protein, it would be expected that it has some
physiological significance. However, its function in smooth muscle cells is still not
completely clear. NM-MHC expression increases during smooth muscle cell proliferation
and atherosclerotic processes (Kawamoto and Adelstein 1987; Kuro-o et al. 1991; Simons
et al. 1993; Simons and Rosenberg 1992). Thus, it has been proposed that non-muscle
myosin is involved in the proliferative phenotype of smooth muscle cells. However, there
was no evidence about the participation of NM-MHC in the contractile phenotype of
smooth muscle cells.
A preferential localization of non-muscle myosin in the cytoskeletal domain has been
suggested, proposing that this isoform may not be involved in smooth muscle contraction
(Murphy et al. 1997). This hypothesis of intracellular compartimentation of myosin
isoforms is mainly supported by a study showing a primarily localization of non-muscle
actin isoform in the dense bodies and near the intermediate filaments, while smooth
muscle specific actin isoform was localized surrounding the thick filaments (North et al.
1994a). Since the expression of non-muscle myosin and actin are thought to be
coordinated (Gaylinn et al. 1989), the evidence of actin isoforms compartments in smooth
muscle cells would suggest a parallel localization of non-muscle myosin isoforms in the
cytoskeletal domain. However, a study with isolated native thin filaments showed that
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different isoactin monomers were present in an individual thin filament (Drew et al. 1991),
thus arguing against the intracellular compartimentation of actin isoforms, and
consequently of myosin isoforms.
According to the above studies, it is generally believed that the non-muscle myosin
isoforms respond to cellular functions, like proliferation and migration, but have no
participation in the contractile function of smooth muscle cells. Nevertheless, most
information about the function of non-muscle and smooth muscle myosin isoforms has
come from in vitro studies. In the present study, the experimental animal model used
allowed to specifically investigate the function of NM-MHC in vivo. Thus, for the first time
the participation of non-muscle myosin in the contractile function of smooth muscle cells
under physiological conditions was shown.
The second important finding of this study is that smooth muscle cells from neonatal mice
could switch from one myosin isoform to another during prolonged stimulation. The
smooth muscle preparations from wild-type mice showed an initial phase of high force
generation (phase 1), followed by a sustained phase of contraction (phase 2). Similar
preparations from SM-MHC deficient mice, however, showed only a sustained contraction,
without a phase 1. In addition, the muscle preparations from knockout mice showed
similar contractile (isometric force) and kinetic (shortening velocity) features as the phase
2 of wild-type preparations. Thus, it seems that SM-MHC is recruited for the phase 1,
whereas NM-MHC is used subsequently for force maintenance (phase 2). The
involvement of NM-MHC in phase 2 of normal neonatal bladder is reinforced by the
existence of longitudinally arranged NM-MHC filaments in wild-type smooth muscle cells
by immunofluorescence microscopy, similar to the NM-MHC filamentous structures
observed in the cell cultures from knockout mice. In fact, using the Nitella-based in vitro
motility assay, Umemoto et al. showed that NM-MHC from human platelets moved actin
filaments much slower than SM-MHC from aorta or trachea bovine and turkey gizzard
smooth muscle (Umemoto et al. 1989). This difference observed in the movement of
smooth muscle and non-muscle (platelets) myosin could explain the lower Vmax of phase
2, in comparison with phase 1 of contraction, thus supporting our hypothesis of
involvement of NM-MHC in phase 2 of wild-type contraction.
Some studies have shown that shortening velocity or ATPase activity can be modified
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during the course of a contraction. Initially, the increase in intracellular Ca2+ leads to
MLC20 phosphorylation and tension generation. During this phase, myosin ATPase activity
is high, as well as ATP utilization and oxygen consumption. Subsequently, myosin
ATPase activity, ATP utilization and oxygen consumption fall, but tension is maintained
(Summerville and Hartshorne 1986). Several different regulatory processes have been
proposed to explain this characteristic, called “latch state” (Dillon et al. 1981). The low
Vmax obtained in the sustained contraction of wild-type and knockout mice, in the present
study, is in accordance with the low ATPase activity and low energy consumption during
the “latch state”, since there is a close correlation between maximal shortening velocity
and myosin ATPase activity (Bárány 1967).
Besides the low ATPase activity, there is also a decrease in the intracellular levels of Ca2+
during the “latch state”. Interestingly, Ca2+-independent phosphorylation of non-muscle
myosin and contraction of non-muscle cells (expressing exclusively NM-MHC) and Ca2+-
sensitization of smooth muscle cells (expressing both SM- and NM-MHC) were recently
reported (Kolodney et al. 1999; Somlyo et al. 1999). Therefore, switching to NM-MHC
during prolonged smooth muscle activation could serve as an additional mechanism
explaining force generation despite decline of Ca2+ to almost basal levels during the “latch
state”. In fact, both wild-type and SM-MHC deficient neonatal bladder preparations
revealed a similar intracellular Ca2+ transient, i.e. high, initial intracellular Ca2+ peak, which
dropped to almost basal levels during sustained contraction (Arner, personal
communication).   
Another important finding of this study is the involvement of protein kinase C (PKC) in the
recruitment of non-muscle myosin. Smooth muscle preparations from both wild-type and
knockout mice showed a similar sustained contraction upon stimulation with phorbol ester.
Thus, during phorbol ester stimulation, NM-MHC may be recruited in both wild-type and
knockout preparations.
Tumor-promoting phorbol esters have been shown to directly activate PKC, probably due
to its analogous structure to diacylglycerol (Castagna et al. 1982; Niedel et al. 1983). In
the present study, pre-incubation with a specific protein kinase C inhibitor completely
abolished the force generated upon stimulation with phorbol ester in both wild-type and
knockout muscle preparations, thus confirming the activation of PKC as being responsible
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for the force produced by phorbol ester stimulation.
Non-muscle myosin II, similarly to smooth muscle myosin, is primarily activated through
phosphorylation of the regulatory light chains of myosin (MLC20). Phosphorylation of non-
muscle and smooth muscle MLC20 at Ser19 regulates its ATPase activity and the
assembly of myosin into filaments (Bresnick 1999; Trybus 1996). In smooth muscle,
MLC20 phosphorylation is mediated by Ca
2+-calmodulin-activated myosin light chain kinase
(MLCK) (Kamm and Stull 1985). In non-muscle cells, not only Ca2+-activation of MLCK
(Sellers et al. 1981), but other Ca2+-independent pathways are believed to be involved in
non-muscle myosin activation (Kolodney et al. 1999). Activation of protein kinase C with
phorbol esters has been shown to stimulate phosphorylation of the MLC20 in non-muscle
cells in both in vitro and in vivo (Ikebe and Reardon1990; Kawamoto et al. 1989; Naka et
al. 1983; Strassheim et al. 1999). However, the effects of PKC-induced MLC20
phosphorylation remain unclear, since PKC phosphorylation of MLC20 was not associated
with increase of ATPase activity of both smooth muscle and non-muscle myosin in the in
vitro studies (Ikebe and Reardon 1990; Nishikawa et al. 1984), or with myosin movement
in the Nitella-based motility assay (Umemoto et al. 1989). On the contrary, another study
with embryonic smooth muscle myosin isoform (NMB) showed that PKC phosphorylation
induced an increase in myosin ATPase activity (de Lanerolle and Nishikawa 1988).
Another possible pathway for PKC-induced activation of non-muscle myosin is through the
inhibition of myosin light chain phosphatase (MLCP). As in smooth muscle, inhibition of
MLCP activity appears to be an important regulatory mechanism for non-muscle cell
contraction (Somlyo and Somlyo 2000). Interestingly, a recent study showed that
activation of PKC in human platelet induced phosphorylation of CPI, leading to inhibition
of MLCP activity and consequently to increased MLC20 phosphorylation (Watanabe et al.
2001). It has been suggested that platelet CPI is a homologous protein of smooth muscle
CPI-17, a phosphorylation-dependent inhibitory protein for myosin light chain
phosphatase. Thus, CPI phosphorylation by PKC may participate in the regulation of non-
muscle myosin activity.
MLC20 phosphorylation catalysed by Ca
2+-calmodulin-dependent MLCK activation is the
main mechanism for initiating contraction in smooth muscle cells. However, other
important mechanisms that modulate Ca2+-sensitivity of smooth muscle contraction
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appear to be important (Somlyo and Somlyo 1999). Several studies support the
participation of PKC in sustained contractions of smooth muscle. Activation of PKC
through phorbol ester produces sustained contraction of various types of smooth muscle
(Park and Rasmussen, 1985; Rasmussen et al. 1984; Yoshida et al. 1992). In the present
study, pre-incubation with phorbol ester significantly potentiated the sustained phase of
KCl-induced contraction, whereas a minimal effect was observed in the first phase of
contraction. 
In conclusion, non-muscle myosin is recruited during prolonged KCl-induced sustained
contraction, while SM-MHC is recruited early during initial KCl activation. Additionally,
protein kinase C activation through stimulation with phorbol ester recruits non-muscle
myosin.
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SUMMARY
The aim of the present study was to investigate the involvement of non-muscle myosin
heavy chain in smooth muscle contraction under physiological conditions. As an
experimental model urinary bladder from neonatal wild-type mice as well as from neonatal
mice with disrupted smooth muscle myosin heavy chain expression was used. This animal
model was established through gene targeting technology, resulting in complete
elimination of the expression of smooth muscle myosin heavy chains. The lack of
expression of smooth muscle myosin heavy chains was confirmed by electrophoresis and
immunoblotting. On the other hand, non-muscle myosin heavy chain expression remained
normal, as verified by Western blot analysis.
The mechanical analysis of smooth muscle was performed with intact urinary bladder
preparations, stimulated using prolonged KCl depolarization or with phorbol ester.
Prolonged activation by KCl depolarization of intact bladder preparations from wild-type
neonatal mice produced an initial transient state (phase 1) of high force generation and
maximal shortening velocity, followed by a sustained state (phase 2) with lower force
generation and maximal shortening velocity. In contrast, bladder preparations from
homozygous knockout neonatal mice did not exhibit phase 1, but phase 2 could be
observed, i.e. a similar isometric force and maximal shortening velocity, compared to wild-
type phase 2. Thus, non-muscle myosin appears to be recruited in the sustained phase of
smooth muscle contraction during prolonged KCl depolarization in the animal model used.
Upon stimulation with phorbol ester a similar sustained contraction was observed in both
wild-type and knockout smooth muscle preparations. Therefore, non-muscle myosin may
also be recruited during phorbol ester stimulation in both wild-type and knockout muscle
preparations.
The participation of non-muscle myosin in smooth muscle contraction was further
supported by the finding of longitudinally arranged intracellular filaments in cultivated
smooth muscle cells from both wild-type and knockout mice by immunofluorescence
microscopy, using a specific antibody raised against non-muscle myosin heavy chain. In
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a similar way, smooth muscle myosin heavy chain structures were investigated in
cultivated smooth muscle cells. As expected, longitudinally arranged intracellular
filamentous structures of smooth muscle myosin were observed in wild-type smooth
muscle cells, but not in smooth muscle cells from knockout mice.
In conclusion, in neonatal smooth muscle the initial phase of contraction elicited by KCl
depolarization is generated by smooth muscle myosin heavy chain recruitment. Upon
prolonged KCl depolarization non-muscle myosin is recruited in the sustained phase of
contraction, as well as upon stimulation with phorbol ester. Thus, it was possible, for the
first time, to verify the involvement of the non-muscle myosin in smooth muscle
contraction in vivo. The results of the present study contribute to the understanding of the
regulatory mechanisms of smooth muscle contraction.
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ZUSAMMENFASSUNG
Das Ziel dieser Studie war es, die Beteiligung der nichtmuskulären schweren
Myosinketten an der Kontraktion der glatten Muskeln unter physiologischen Bedingungen
zu untersuchen. Als Versuchsmodell wurde die Harnblase von neugeborenen Wildtyp und
transgenen Mäusen verwendet, bei denen das Gen für die glattmuskelspezifischen
schweren Myosinketten durch „Gene Targeting“  funktionell eliminiert  wurde (Knock-Out).
Das Fehlen der Expression der glattmuskelspezifischen schweren Myosinketten wurde
durch Elektrophorese und Immunfärbung bestätigt. Im Gegensatz dazu blieb die
Expression der nichtmuskulären schweren Myosinketten unverändert.
Die mechanische Analyse des glatten Muskels wurde mit intakten Muskelpräparaten aus
der Harnblase durchgeführt. Das Muskelpräparat wurde in KCl-Lösung oder mit
Phorbolester stimuliert. Die Aktivierung mittels depolarisierender KCl-Lösung führte bei
neugeborenen Wildtyp Mäusen zuerst zu einer transienten Kontraktion (Phase 1) mit
hoher Kraftentwicklung und maximaler Verkürzungsgeschwindigkeit, und danach zu einer
tonischen Kontraktion (Phase 2) mit niedrigerer Kraftentwicklung und maximaler
Verkürzungsgeschwindigkeit. Blasenpräparate neugeborener Knock-Out Mäuse dagegen
zeigten keine Phase 1, sondern nur eine tonische Kontraktion, die mit Wildtyp Mäusen
vergleichbar war. Daher scheint nichtmuskuläres Myosin an der tonischen Kontraktion des
glatten Muskels beteiligt zu sein.
Durch Stimulierung mit Phorbolester waren ähnliche tonische Muskelkontraktionen der
Blasenpräparate sowohl bei Wildtyp als auch bei Knock-Out Mäusen zu beobachten.
Vermutlich wird also das nichtmuskuläre Myosin durch Stimulierung mit Phorbolester
aktiviert.
Intrazelluläre Filamente wurden durch Immunfluoreszenz mit einem spezifischen
Antikörper gegen nichtmuskuläre schwere Myosinketten in kultivierten primären glatten
Muskelzellen untersucht. Dabei zeigten die Muskelzellen sowohl von Wildtyp als auch von
Knock-Out Mäusen intrazelluläre dicke Myosinfilamente, was für die Beteiligung des
nichtmuskulären Myosins an der glatten Muskelkontraktion spricht. Entsprechend wurden
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intrazelluläre Filamente mit einem Antikörper gegen glattmuskelspezifische schwere
Myosinketten in kultivierten primären glatten Muskelzellen untersucht. Wie erwartet,
konnten nur in glatten Muskelzellen von Wildtyp Mäusen intrazelluläre Filamente
nachgewiesen werden, nicht aber in denen von Knock-Out Mäusen. 
In dieser Arbeit konnte zum ersten Mal gezeigt werden, dass nichtmuskuläres Myosin
zumindest an der tonischen Kontraktion glatter Muskelzellen beteiligt sein kann.
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